Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD7 is a transmembrane glycoprotein and a member of the immunoglobulin superfamily, primarily expressed on T cells, natural killer (NK) cells, and their precursors. It acts as a costimulatory molecule involved in T cell activation and differentiation and plays a role in immune response modulation, including apoptosis. It is a target for immunotherapies, particularly CAR-T therapies, for treating hematologic malignancies, but fratricide among CAR-T cells remains a challenge. CD8+ T cell populations can be subdivided based on surface levels of CD7, with high levels indicating naive/memory subsets and low/negative levels indicating effector populations.
Antibody-mediated cytotoxicity; CAR-T cell mediated cytotoxicity; Apoptosis induction via galectin-1 binding
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell antigen CD7 (CD7).